---
layout: default
title: Rocuronium
parent: Model Prediction Only (L5)
nav_order: 691
evidence_level: L5
indication_count: 10
---

# Rocuronium
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Rocuronium: From Neuromuscular Blockade (Anesthesia Adjunct) to Migraine Disorder

## One-Sentence Summary

Rocuronium is a non-depolarizing neuromuscular blocking agent (NMBA) conventionally used as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery. The TxGNN model predicts a possible association with **Migraine Disorder**, with a very high raw prediction score (**99.90%**), but currently only **1 marginally relevant clinical trial** and **no supporting literature** back this direction. Given the drug's strictly peripheral mechanism, this prediction most likely reflects knowledge-graph noise rather than a genuine pharmacological signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this evidence pack (Canada: not marketed, no license text available). Pharmacologically classified as a non-depolarizing NMBA used as a general anesthesia adjunct. |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

DrugBank's formal mechanism-of-action text is flagged as a data gap (DG002) in this evidence pack. However, the underlying pharmacology is well established: Rocuronium is a quaternary ammonium, non-depolarizing neuromuscular blocking agent that competitively antagonizes nicotinic acetylcholine receptors at the peripheral neuromuscular junction. As a quaternary ammonium compound, it does not cross the blood–brain barrier and has no known central nervous system activity.

Migraine pathophysiology, by contrast, is understood to involve trigeminovascular activation, CGRP-mediated neurogenic inflammation, and central sensitization within the CNS — none of which overlap with rocuronium's peripheral site of action. There is no described biological pathway connecting peripheral neuromuscular blockade to migraine pathogenesis or relief.

Given this mechanistic mismatch, the TxGNN model's high score for this drug–disease pair most plausibly reflects a knowledge-graph embedding artifact — for example, node proximity arising from rocuronium's frequent co-occurrence in general-anesthesia clinical trial records — rather than genuine pharmacological plausibility. This interpretation is consistent with the evidence pack's own annotation, which explicitly flags the score as likely embedding noise.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT01431326](https://clinicaltrials.gov/study/NCT01431326) | N/A | Completed | 3,520 | Pediatric pharmacokinetics study of understudied drugs administered per standard of care; rocuronium was one of many study drugs. Not designed to evaluate migraine treatment — graded C relevance (indirect, non-specific to migraine). |

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

Rocuronium currently holds **no Health Canada drug identification numbers (DINs)** in this evidence pack (`total_licenses = 0`, `market_status = Not marketed / Not Marketed`). No authorized indication text is available for review.

---

## Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug–drug interaction data are all currently unavailable in this evidence pack (DG001, Blocking severity).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The predicted indication (Migraine Disorder) lacks mechanistic plausibility — rocuronium acts exclusively at the peripheral neuromuscular junction and does not cross the blood–brain barrier, while migraine pathophysiology is centrally mediated.
- Evidence level is L5: the single associated clinical trial is an unrelated pediatric PK study, and no supporting literature exists.
- A Blocking-severity data gap (DG001: missing TFDA/Health Canada label warnings and contraindications) prevents any safety pre-assessment (S1), independent of the indication question.

**To proceed, the following is needed:**
- TFDA/Health Canada product monograph (warnings, contraindications) to close Blocking gap DG001 before any S1 safety screening can occur.
- Confirmed DrugBank mechanism-of-action text (DG002) to formally document the CNS-exclusion rationale.
- If migraine is to remain under consideration, independent mechanistic or preclinical evidence directly linking NMBA pharmacology to migraine pathways — none currently exists.
- Given the mechanistic and evidentiary weaknesses, no further resources should be allocated to this candidate unless new primary evidence emerges.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

